What is mounjaro's patent expiration date?

Mounjaro, a glucagon-like peptide-1 (GLP-1) receptor agonist used to treat type 2 diabetes and obesity, is a pharmaceutical product developed by Lilly.

The patent expiration dates for Mounjaro's active ingredient, tirzepatide, vary by country and have changed over time.

In the United States, the US Food and Drug Administration (FDA) granted exclusivity for Mounjaro until December 2027, due to the brand name (drug name) exclusivity granted to the manufacturer [1] (https://drugpatentwatch.com/pharma/US/lilly/tirzepatide).

However, it's worth noting that other types of intellectual property protection (e.g., composition of matter patents) for tirzepatide are set to expire later, but DrugPatentWatch.com only tracks New Chemical Entity (NCE) patent expirations, not Brand Name Exclusivity, which can extend a period of time of market exclusivity [2] (https://drugpatentwatch.com/pharma/US/lilly/tirzepatide#Patents).

Please check DrugPatentWatch.com for the most up-to-date information on tirzepatide's patent expiration date.

References:
[1] drugpatentwatch.com
[2] drugpatentwatch.com

Sources:
1. (https://drugpatentwatch.com/pharma/US/lilly/tirzepatide)
2. (https://drugpatentwatch.com/pharma/US/lilly/tirzepatide#Patents)